Related Experiment Video
Updated: Aug 14, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
An update on the use of ophthalmic ketorolac tromethamine 0.4%
Henry D Perry1, Eric D Donnenfeld
1Ophthalmic Consultants of Long Island, 2000 North Village Avenue, Rockville Centre, New York 11570, USA. hankcornea@aol.com
Abstract:
Ketorolac tromethamine 0.4% ophthalmic solution, a recent reformulation of the original ketorolac tromethamine 0.5% solution, is indicated for the reduction of ocular pain and burning/stinging following cataract and refractive surgery. Studies have demonstrated that ketorolac tromethamine 0.4% has equivalent efficacy to ketorolac tromethamine 0.5% in reducing postsurgical inflammation and controlling pain. Several studies have demonstrated that, as well as reducing pain and ocular inflammation, ketorolac tromethamine 0.4% effectively treats cystoid macular oedema, inhibits miosis and may prevent cystoid macular oedema when used both pre- and postoperatively. Ketorolac tromethamine 0.4% is a versatile agent and is effective when used as either monotherapy or as an adjunct therapy to steroids.
Related Concept Videos
Ophthalmic Drug Delivery Systems
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
